JP7762168B2 - 腸内微生物叢の生物活性化ｐｄｅ４阻害剤前駆体 - Google Patents

腸内微生物叢の生物活性化ｐｄｅ４阻害剤前駆体

Info

Publication number
JP7762168B2
JP7762168B2 JP2022573665A JP2022573665A JP7762168B2 JP 7762168 B2 JP7762168 B2 JP 7762168B2 JP 2022573665 A JP2022573665 A JP 2022573665A JP 2022573665 A JP2022573665 A JP 2022573665A JP 7762168 B2 JP7762168 B2 JP 7762168B2
Authority
JP
Japan
Prior art keywords
group
compound
disease
pyridin
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022573665A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023528397A (ja
JP2023528397A5 (https=
Inventor
コテ，ベルナール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Giiant Pharma Inc
Original Assignee
Giiant Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Giiant Pharma Inc filed Critical Giiant Pharma Inc
Publication of JP2023528397A publication Critical patent/JP2023528397A/ja
Publication of JP2023528397A5 publication Critical patent/JP2023528397A5/ja
Application granted granted Critical
Publication of JP7762168B2 publication Critical patent/JP7762168B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2022573665A 2020-05-28 2021-05-28 腸内微生物叢の生物活性化ｐｄｅ４阻害剤前駆体 Active JP7762168B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063031023P 2020-05-28 2020-05-28
US63/031,023 2020-05-28
PCT/CA2021/050725 WO2021237364A1 (en) 2020-05-28 2021-05-28 Gut microbiota bioactivated pde4 inhibitor precursors

Publications (3)

Publication Number Publication Date
JP2023528397A JP2023528397A (ja) 2023-07-04
JP2023528397A5 JP2023528397A5 (https=) 2024-06-04
JP7762168B2 true JP7762168B2 (ja) 2025-10-29

Family

ID=78745382

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022573665A Active JP7762168B2 (ja) 2020-05-28 2021-05-28 腸内微生物叢の生物活性化ｐｄｅ４阻害剤前駆体

Country Status (9)

Country Link
US (1) US20230250123A1 (https=)
EP (1) EP4157853B1 (https=)
JP (1) JP7762168B2 (https=)
KR (1) KR20230029682A (https=)
CN (1) CN116056713B (https=)
AU (1) AU2021280418A1 (https=)
ES (1) ES2989065T3 (https=)
MX (1) MX2022014416A (https=)
WO (1) WO2021237364A1 (https=)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004005258A1 (en) 2002-07-02 2004-01-15 Merck Frosst Canada & Co. Di-aryl-substituted-ethane pyridone pde4 inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6200993B1 (en) * 1999-05-05 2001-03-13 Merck Frosst Canada & Co. Heterosubstituted pyridine derivatives as PDE4 inhibitors
MY123585A (en) * 2000-03-23 2006-05-31 Merck Canada Inc Tri-aryl-substituted-ethane pde4 inhibitors.
WO2007142929A2 (en) * 2006-05-31 2007-12-13 The University Of North Carolina At Chapel Hill Novel pde4 inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004005258A1 (en) 2002-07-02 2004-01-15 Merck Frosst Canada & Co. Di-aryl-substituted-ethane pyridone pde4 inhibitors

Also Published As

Publication number Publication date
MX2022014416A (es) 2023-02-22
KR20230029682A (ko) 2023-03-03
JP2023528397A (ja) 2023-07-04
EP4157853B1 (en) 2024-07-31
CN116056713B (zh) 2025-09-09
US20230250123A1 (en) 2023-08-10
CN116056713A (zh) 2023-05-02
ES2989065T3 (es) 2024-11-25
WO2021237364A1 (en) 2021-12-02
AU2021280418A1 (en) 2023-02-02
CA3174137A1 (en) 2021-12-02
EP4157853A1 (en) 2023-04-05
EP4157853A4 (en) 2023-12-13
EP4157853C0 (en) 2024-07-31

Similar Documents

Publication Publication Date Title
US10428027B2 (en) Sulfinylphenyl or sulfonimidoylphenyl benzazepines
US10647711B2 (en) Azepin-2-one derivatives as RSV inhibitors
CN111801339B (zh) 5-氟尿嘧啶化合物
RU2503673C2 (ru) Новое производное 5-фторурацила
US9440960B2 (en) Substituted oxetanes and their use as inhibitors of cathepsin C
US9890176B2 (en) Mannose derivatives for treating bacterial infections
US12006326B2 (en) Antiviral heterocyclic compounds
AU2007288281A1 (en) Compounds and methods for inhibiting the interaction of Bcl proteins with binding partners
US12162857B2 (en) Antiviral compounds
US20140107049A1 (en) Mannose derivatives for treating bacterial infections
US20220119398A1 (en) Heterocyclic compounds as anti-viral agents
US20200399227A1 (en) 5-fluorouracil compounds
WO2015027963A1 (zh) 芳环类衍生物、其药物组合物及其应用
KR102682408B1 (ko) 신규한 벤조티아졸 유도체, 이의 제조방법 및 이의 간질환 예방 또는 치료 용도
US20250368621A1 (en) Csf-1r inhibitors and methods of use thereof
JP7762168B2 (ja) 腸内微生物叢の生物活性化ｐｄｅ４阻害剤前駆体
CA3174137C (en) Gut microbiota bioactivated pde4 inhibitor precursors
WO2006059163A1 (en) Treatment of diabetes with glycogen phosphorylase inhibitors
HK40093996A (zh) 肠道微生物群生物活性pde4抑制剂前体
CN121002023A (zh) 趋化因子受体调节剂制备方法和用途
TW201839005A (zh) 對多重耐藥菌有效之新穎胺基糖苷抗生素
JPWO2009041475A1 (ja) ピラゾール−３−イル−ベンズアミド誘導体の製造方法
WO2018172129A1 (de) Sialinsäurederivate mit c-c dreifachbindung und deren herstellung
US20250154163A1 (en) Pyrimidinone-Containing 17-Beta-Hydroxysteroid Dehydrogenase Type 13 Inhibitors
US11179400B2 (en) Heterocyclic compounds as RSV inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240527

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240527

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250709

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250916

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251008

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251017

R150 Certificate of patent or registration of utility model

Ref document number: 7762168

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150